

Date: 04.08.2025

To
Bombay Stock Exchange Limited
25th Floor, PJ Towers
Dalal Street,
Mumbai-400001
Scrip Code: 524654

To
National Stock Exchange of India Limited
Exchange Plaza , C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: NATCAPSUQ

Sub: Outcome of Board Meeting held on Monday, August 04, 2025

Dear Sir/Madam,

This is to inform that the Board of the Directors at their meeting held on Monday, August 04, 2025, approved the Unaudited Consolidated & Standalone Financial Results of the company for the Quarter ended 30th June, 2025. In connection with this, please find enclosed herewith Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for the quarter ended June 30, 2025.

Pursuant to Regulation 30(5) of the SEBI (LODR) Regulations, the following persons are authorized by the Board of Directors to determine materiality of an event/information and to make necessary disclosures to stock exchange(s) with effect from 4th August 2025:

Purpose	Authorized Person	Contact details
Determining Materiality	Mr. Sunil L Mundra, Managing Director	Trident Towers, 3rd Floor, No. 23, 100 Feet Road, Jaynagar II Block, Bengaluru, Karnataka, 560011 Contact No: +91 8026671571 Email ID: Corporate@naturalcapsules.com
Submission of Disclosure	Ms. Pranjal Deshmukh, Company Secretary & Compliance Officer	

The Board Meeting commenced at 04.38 PM and concluded at 05.30 PM.

We request you to kindly take the aforesaid information on record.

Thanking You

Yours Faithfully,

For Natural Capsules Limited

Sunil L Mundra
Managing Director
DIN: -00214304



P. CHANDRASEKAR LLP

Chartered Accountants


Independent Auditor's Limited Review Report on standalone unaudited financial results of for the quarter ended 30 June 2025 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

TO

The Board of Directors,
Natural Capsules Limited,
Bangalore.

1. We have received the accompanying statement of unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** ("the company") for the quarter ended June 2025 ("the Statement"), which are included in the accompanying statement of unaudited financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **P. Chandrasekar LLP**
Chartered Accountants
FRN No: 000580S/S200066


Rajesh D

Partner

Membership No:234709

UDIN : 25234709BNUIRQ6524

Place: Bangalore

Date: 4th August 2025



Bangalore / Chennai / Hyderabad

Head Office:

S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042

☎ : 080-25585443 / 25597494

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025.

Rs in Lakhs

Sl. No.	PARTICULARS	Quarter Ended			Year Ended
		30th June 2025	31st Mar 2025	30th June 2024	31st Mar 2025
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	4,424.29	4,436.07	3,913.59	16,793.82
2	Other Income	169.08	154.94	76.49	423.54
3	Total Income (1+2)	4,593.37	4,591.02	3,990.08	17,217.36
4	Expenses				
	a) Cost of Material consumed	2,210.06	2,213.23	2,041.72	8,512.12
	b) (Increase) / Decrease in stock in trade	63.97	21.46	-46.47	-113.45
	c) Purchase of stock-in-trade	-	-	-	-
	d) Employees benefits expense	361.30	358.12	323.09	1,373.94
	f) Finance cost	135.75	152.47	145.63	591.01
	g) Depreciation	199.02	194.20	209.28	832.85
	h) Other Expenses	1,275.48	1,338.32	1,123.18	5,091.23
	Total Expenses	4,245.58	4,277.80	3,796.43	16,287.70
5	Profit from ordinary activities after finance costs but before exceptional items	347.79	313.22	193.65	929.66
6	Exceptional Items Income / (Expenses)	-	-	-	-
7	Profit from ordinary activities before tax	347.79	313.22	193.65	929.66
8	Tax Expense	95.49	50.56	47.73	258.54
	- Current Tax	88.38	57.82	45.90	207.39
	- Income tax (Prior year)	-	-84.84	-	-84.84
	- Deferred Tax	7.11	77.59	1.84	136.00
9	Net Profit (+) / Loss (-) from ordinary activities after tax	252.30	262.66	145.91	671.11
10	Other Comprehensive income (OCI)				
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-38.49	-	-38.49
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	252.30	224.17	145.91	632.62
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,034.12	1,034.12	934.22	1,034.12
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-				
	(a) Basic	2.44	2.17	1.56	6.43
	(b) Diluted	2.44	2.17	1.56	6.43

Note:

- The above unaudited standalone financial results of Natural Capsules Limited (the Company) for the quarter ended 30th June 2025 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 4th August 2025. The above results have been subjected to "Limited Review" by the statutory auditors of the Company and they have expressed an unmodified conclusion.
- The above unaudited standalone financial results for the quarter ended 30th June, 2025 have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- Previous years figures have been regrouped wherever necessary.
- Position of investor complaints for the quarter ended 30th June, 2025

Particulars

Pending as on 01.04.2025	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30.06.2025	Nil

For and on behalf of the Board


Sunil Mundra
Managing Director

DIN:00214304

Place : Bangalore

Date : 04-08-2025



P. CHANDRASEKAR LLP

Chartered Accountants

Independent Auditor's Limited Review Report on Consolidated unaudited financial results of for
the quarter ended 30 June 2025 pursuant to the Regulation 33 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended

TO

The Board of Directors,
Natural Capsules Limited
Bangalore

1. We have received the accompanying statement of Consolidated unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), for the quarter ended June 2025 ("the Statement"), which are included in the accompanying statement of consolidated unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
 2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our Responsibility is to issue a report on the statement of consolidated unaudited financial results based on our review.
 3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary



Bangalore / Chennai / Hyderabad

Head Office:

S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042


☎ : 080-25585443 / 25597494

P. CHANDRASEKAR LLP

Chartered Accountants

5. The accompanying Statement includes the unaudited financial statements and other financial information, In respect of two subsidiaries, whose financial statements, without giving the effect to elimination of intra group transactions, Include total revenue of 10.26 lacs and net loss after tax of Rs.45.05 lacs, as considered in the consolidated unaudited financial results June 2025.
6. We did not review the interim financial results of one subsidiary Natural Phyto Pharma Private Limited included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs.2.87 lacs as at 30th June 2025 and total revenues of Rs. Nil for the quarter ended 30th June 2025, total net profit after tax of Rs. Nil for the quarter ended 30th June 2025 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.
7. Based on our review conducted as above and based on the consideration of the review financial results/financial information certified by the Management as given above in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S200066


Rajesh D

Partner

Membership No: 234709

UDIN: 25234709BNUIRP6577



Place: Bangalore

Date: 4th August 2025

Bangalore / Chennai / Hyderabad

Head Office:

S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042

☎ : 080-25585443 / 25597494

NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

Rs in Lakhs

Sl. No.	PARTICULARS	Quarter Ended			Year Ended
		30th Jun 2025	31st Mar 2025	30th June 2024	31st Mar 2025
		Unaudited	Audited	Unaudited	Audited
1	Revenue from operations	4,520.31	4,497.04	3,918.34	16,920.55
2	Other Income	35.85	30.43	18.35	70.36
3	Total Income (1+2)	4,556.16	4,527.47	3,936.70	16,990.92
4	Expenses				
	a) Cost of Material consumed	2,358.03	2,294.82	2,038.36	8,688.02
	b) (Increase) / Decrease in stock in trade	-0.65	-14.29	-39.78	-197.47
	c) Purchase of stock-in-trade	-	-	-	-
	d) Employees benefits expense	537.61	371.16	330.68	1,412.74
	f) Finance cost	253.03	163.85	148.76	631.31
	g) Depreciation	421.18	215.62	227.98	911.80
	h) Other Expenses	1,593.40	1,407.18	1,152.50	5,265.42
	Total Expenses	5,162.60	4,438.34	3,858.50	16,711.82
	Profit from ordinary activities after finance costs but before exceptional items	-606.44	89.13	78.20	279.10
5	Exceptional Items Income / (Expenses)	-	-	-	-
6	Profit from ordinary activities before tax	-606.44	89.13	78.20	279.10
7	Tax Expense	-48.39	37.05	17.87	217.36
	- Current Tax	88.38	57.82	33.39	207.39
	- Income tax (Prior year)	-	-84.84	-	-84.84
	- Deferred Tax	-136.77	64.08	-15.52	94.81
8	Net Profit (+) / Loss (-) from ordinary activities after tax	-558.05	52.07	60.33	61.74
9	Other Comprehensive income (OCI)				
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-39.01	-	-39.01
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-
10	Total Comprehensive Income (OCI) for the period	-558.05	13.06	60.33	-22.73
11	Paid-Up Equity Share Capital (face value per share Rs. 10/-)	1,034.12	1,034.12	934.22	1,034.12
12	Earnings Per Share of (before & after extraordinary items) Rs. 10/-				
	(a) Basic	-5.40	0.13	0.65	0.22
	(b) Diluted	-5.40	0.13	0.65	0.22

Note:

- The above unaudited consolidated financial results of Natural Capsules Limited (the Company) for the quarter ended 30th June 2025 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 4th August 2025. The above results have been subjected to "Limited Review" by the statutory auditors of the Company and they have expressed an unmodified conclusion.
- The above unaudited consolidated financial results for the quarter ended 30th June, 2025 have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
- The subsidiary company Natural Biogenex Private Limited company has obtained the Consent for Operation (CFO) from Karnataka Pollution Control Board in the month of January 2025. The company has commenced the commercial operation on 31st March 2025 and accordingly the cost incurred till the date of commencement of commercial operation are considered as pre-operative expenses as
- The subsidiary company Natural Biogenex Private limited has started the commercial operation on 31st March 2025, all expenses for the quarter ended 30th June 2025 charged to Profit & Loss Account, however full revenue potential yet to be achieved and therefore there is a higher loss in the current quarter and hence previous quarters figures are not comparable.
- Previous years figures have been regrouped wherever necessary.
- Position of investor complaints for the quarter ended 30th June, 2025

Particulars

Pending as on 01.04.2025	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 30-06-2025	Nil

For and on behalf of the Board


Sunil L. Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 04-08-2025



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

CONSOLIDATED SEGMENT WISE REVENUE, RESULTS & CAPITAL EMPLOYED

Rs in Lakhs

PARTICULARS	Quarter Ended			Year Ended
	30th Jun 2025	31st Mar 2025	30th June 2024	31st Mar 2025
	Unaudited	Audited	Unaudited	Audited
1. Segment Revenue				
(a) Capsules	4,424.29	4,436.07	3,913.59	16,793.82
(b) API	96.02	60.97	4.76	126.73
(c) Unallocated				
Total	4,520.31	4,497.04	3,918.34	16,920.55
Less: Inter Segment Revenue	-	-	-	-
Income from Operations	4,520.31	4,497.04	3,918.34	16,920.55
2. Segment Results, Profit(+)/Loss (-) before tax and interest from each segment				
(a) Capsules	483.54	338.13	275.63	1,149.99
(b) API	-698.55	-85.15	-48.67	-239.59
(c) Unallocated	-	-	-	-
Total	-215.01	252.98	226.96	910.41
Less: (i) Interest	399.34	163.85	148.76	631.31
(ii) Other Un-allocable Expenditure	-	-	-	-
(iii) Un-allocable Income	-7.91	-	-	-
Total Profit Before Tax	-606.44	89.13	78.20	279.10
3. Segment Assets				
(a) Capsules	18,984.93	18,989.89	18,476.41	18,989.89
(b) API	22,873.09	22,945.26	19,400.75	22,945.26
(c) Unallocated	-	-	-	-
(d) Others	-	-	-	-
Total	41,858.02	41,935.15	37,877.16	41,935.15
4. Segment Liabilities				
(a) Capsules	5,216.04	4,623.71	3,936.24	4,623.71
(b) API	723.10	1,214.75	174.55	1,214.75
(c) Unallocated	-	-	-	-
(d) Others	-	-	-	-
Total	5,939.14	5,838.46	4,110.78	5,838.46
5. Capital Employed (Segment Assets-Segment Liabilities)				
(a) Capsules	13,768.89	14,366.18	14,540.17	14,366.18
(b) API	22,149.99	21,730.51	19,226.21	21,730.51
(c) Unallocated	-	-	-	-
(d) Others	-	-	-	-
Total	35,918.88	36,096.69	33,766.38	36,096.69

For and on behalf of the Board


Sunil L. Munda
Managing Director
DIN: 00214304
Place: Bangalore
Date : 04-08-2025

